BRPI0822398B8 - forma sólida cristalina e composição farmacêutica que a compreende - Google Patents
forma sólida cristalina e composição farmacêutica que a compreende Download PDFInfo
- Publication number
- BRPI0822398B8 BRPI0822398B8 BRPI0822398A BRPI0822398A BRPI0822398B8 BR PI0822398 B8 BRPI0822398 B8 BR PI0822398B8 BR PI0822398 A BRPI0822398 A BR PI0822398A BR PI0822398 A BRPI0822398 A BR PI0822398A BR PI0822398 B8 BRPI0822398 B8 BR PI0822398B8
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- solid form
- crystalline solid
- crystalline
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2008/004021 WO2009120167A1 (en) | 2008-03-27 | 2008-03-27 | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0822398A2 BRPI0822398A2 (pt) | 2014-11-18 |
BRPI0822398B1 BRPI0822398B1 (pt) | 2018-01-16 |
BRPI0822398B8 true BRPI0822398B8 (pt) | 2018-05-29 |
Family
ID=40043076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0822398A BRPI0822398B8 (pt) | 2008-03-27 | 2008-03-27 | forma sólida cristalina e composição farmacêutica que a compreende |
Country Status (21)
Country | Link |
---|---|
EP (2) | EP2695616A1 (pt) |
JP (1) | JP5474043B2 (pt) |
KR (3) | KR20100132045A (pt) |
CN (1) | CN102046167A (pt) |
AU (1) | AU2008353468B2 (pt) |
BR (1) | BRPI0822398B8 (pt) |
CA (1) | CA2718601A1 (pt) |
CY (1) | CY1115361T1 (pt) |
DK (1) | DK2276483T3 (pt) |
ES (1) | ES2476252T3 (pt) |
HR (1) | HRP20140609T1 (pt) |
IL (3) | IL208216A0 (pt) |
MX (2) | MX359839B (pt) |
NO (1) | NO2015017I1 (pt) |
NZ (1) | NZ588104A (pt) |
PL (1) | PL2276483T3 (pt) |
PT (1) | PT2276483E (pt) |
RU (1) | RU2471782C2 (pt) |
SI (1) | SI2276483T1 (pt) |
WO (1) | WO2009120167A1 (pt) |
ZA (1) | ZA201006663B (pt) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
EP2695616A1 (en) | 2008-03-27 | 2014-02-12 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
CN107964016B (zh) | 2009-05-14 | 2021-10-01 | 天津合美医药科技有限公司 | 噻吩衍生物 |
US20140004182A1 (en) * | 2009-11-19 | 2014-01-02 | Jerome B. Zeldis | Methods for the treatment of sarcoidosis |
WO2011159750A1 (en) * | 2010-06-15 | 2011-12-22 | Celgene Corporation | Biomarkers for the treatment of psoriasis |
US20140018404A1 (en) * | 2010-12-16 | 2014-01-16 | Celgene Corporation | Controlled release oral dosage forms of poorly soluble drugs and uses thereof |
US9532977B2 (en) | 2010-12-16 | 2017-01-03 | Celgene Corporation | Controlled release oral dosage forms of poorly soluble drugs and uses thereof |
US9387195B2 (en) | 2011-03-07 | 2016-07-12 | Celgene Corporation | Methods for treating diseases using isoindoline compounds |
EP2730278A1 (en) * | 2012-11-08 | 2014-05-14 | Ratiopharm GmbH | Composition melt |
WO2014074846A1 (en) * | 2012-11-09 | 2014-05-15 | Celgene Corporation | Methods for the treatment of bone loss |
JP2014114308A (ja) * | 2014-01-31 | 2014-06-26 | Celgene Corp | (+)−2−[1−(3−エトキシ−4−メトキシフェニル)−2−メチルスルホニルエチル]−4−アセチルアミノイソインドリン−1,3−ジオンを含む固形物形態、その組成物およびその使用 |
IN2014MU01283A (pt) | 2014-04-04 | 2015-10-09 | Cadila Healthcare Ltd | |
US9994522B2 (en) | 2014-05-11 | 2018-06-12 | Mapi Pharma Ltd. | Amorphous form of apremilast |
MX2016014384A (es) | 2014-06-23 | 2017-01-20 | Celgene Corp | Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado. |
CN105294534B (zh) * | 2014-07-15 | 2020-04-10 | 上海优拓医药科技有限公司 | 制备阿普司特及其中间体的产业化方法 |
CN104761484B (zh) | 2014-11-24 | 2018-03-27 | 上海优拓医药科技有限公司 | 一种稳定的不含溶剂化物的阿普司特晶型ii及其制备方法 |
CN104496886A (zh) * | 2014-12-11 | 2015-04-08 | 杭州新博思生物医药有限公司 | 一种高纯度阿普斯特b晶型的制备方法 |
EP3034496A1 (en) * | 2014-12-18 | 2016-06-22 | LEK Pharmaceuticals d.d. | Novel solvates of n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1h-isoindol-4-yl]acetamide |
WO2016135755A1 (en) | 2015-02-27 | 2016-09-01 | Mylan Laboratories Limited | Amorphous apremilast, premixes thereof, and novel crystalline forms of apremilast |
CN107635962A (zh) * | 2015-03-19 | 2018-01-26 | 印度商西伯拉有限公司 | 用于制备阿普斯特的改进工艺 |
WO2016169533A1 (en) | 2015-04-24 | 2016-10-27 | Zentiva, K.S. | A solid form of apremilast and a process for preparing the same |
CN104892486B (zh) * | 2015-06-25 | 2017-12-08 | 济南纽华医药科技有限公司 | 阿普斯特的晶型b+及其制备方法 |
US10544097B2 (en) | 2015-08-27 | 2020-01-28 | Msn Laboratories Private Limited | Solid state forms of N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide and process for preparation thereof |
US9765026B2 (en) * | 2015-08-28 | 2017-09-19 | Scinopharm Taiwan, Ltd. | Forms of apremilast and the process of making the same |
CN105218428A (zh) * | 2015-10-20 | 2016-01-06 | 南京美嘉宁逸医药研究开发有限公司 | 一种高手性纯度的阿普斯特的制备方法 |
WO2017076987A1 (en) * | 2015-11-03 | 2017-05-11 | Ratiopharm Gmbh | Composition comprising apremilast in amorphous form |
CN105330587A (zh) * | 2015-11-27 | 2016-02-17 | 东华大学 | 一种3-乙酰胺基邻苯二甲酰亚胺的制备方法 |
CZ20165A3 (cs) | 2016-01-06 | 2017-07-19 | Zentiva, K.S. | Způsoby přípravy amorfního apremilastu |
US10774042B2 (en) * | 2016-05-12 | 2020-09-15 | Zaklady Farmaceutyczne Polpharma Sa | Crystalline forms of apremilast |
EP3471698A1 (en) | 2016-06-15 | 2019-04-24 | Torrent Pharmaceuticals Limited | Topical compositions of apremilast |
CN106008315A (zh) * | 2016-06-16 | 2016-10-12 | 珠海联邦制药股份有限公司 | 一种阿普斯特晶型s及其制备方法 |
US10196355B2 (en) | 2016-06-20 | 2019-02-05 | Johnson Matthey Public Limited Company | Forms of apremilast |
CN107686461A (zh) * | 2016-08-04 | 2018-02-13 | 广东东阳光药业有限公司 | 阿普斯特的溶剂化物及其制备方法和用途 |
CN110049968A (zh) * | 2016-11-09 | 2019-07-23 | 广东东阳光药业有限公司 | 阿普斯特共晶及其制备方法 |
EP3339292A1 (en) | 2016-12-23 | 2018-06-27 | Zaklady Farmaceutyczne Polpharma SA | Cocrystals of apremilast |
AU2018228541B2 (en) * | 2017-02-28 | 2020-07-16 | Kangpu Biopharmaceuticals, Ltd. | Novel isoindoline derivative, and pharmaceutical composition and application thereof |
AR114666A1 (es) | 2018-03-07 | 2020-09-30 | Celgene Int Ii Sarl | Derivados de isoindolin-1,3-diona, un intermediario para su síntesis, una composición farmacéutica que los comprende y el uso de los mismos en el tratamiento de enfermedades inflamatorias y de cáncer |
EP3929179A1 (en) | 2020-06-22 | 2021-12-29 | Biohorm, S.L. | Anti-inflammatory compounds and methods for their manufacture |
CN115068467A (zh) * | 2021-03-15 | 2022-09-20 | 中国医学科学院药物研究所 | 穿心莲内酯作为ltb4受体抑制剂的医药用途 |
CA3216107A1 (en) | 2021-04-26 | 2022-11-03 | Amgen Inc. | Process for synthesizing apremilast |
EP4183389A1 (en) | 2021-11-18 | 2023-05-24 | KRKA, d.d., Novo mesto | Pharmaceutical composition comprising apremilast |
WO2023118043A1 (en) | 2021-12-22 | 2023-06-29 | Biohorm, S.L. | Pharmaceutical compositions of apremilast |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US6020358A (en) | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
EP2695616A1 (en) | 2008-03-27 | 2014-02-12 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
-
2008
- 2008-03-27 EP EP13182313.0A patent/EP2695616A1/en not_active Withdrawn
- 2008-03-27 KR KR1020107023930A patent/KR20100132045A/ko not_active Application Discontinuation
- 2008-03-27 PL PL08742326T patent/PL2276483T3/pl unknown
- 2008-03-27 WO PCT/US2008/004021 patent/WO2009120167A1/en active Application Filing
- 2008-03-27 DK DK08742326.5T patent/DK2276483T3/da active
- 2008-03-27 KR KR20157005448A patent/KR20150038547A/ko not_active Application Discontinuation
- 2008-03-27 SI SI200831240T patent/SI2276483T1/sl unknown
- 2008-03-27 ES ES08742326.5T patent/ES2476252T3/es active Active
- 2008-03-27 MX MX2013014818A patent/MX359839B/es unknown
- 2008-03-27 NZ NZ588104A patent/NZ588104A/xx unknown
- 2008-03-27 JP JP2011501754A patent/JP5474043B2/ja active Active
- 2008-03-27 CN CN2008801294626A patent/CN102046167A/zh active Pending
- 2008-03-27 MX MX2010010454A patent/MX2010010454A/es active IP Right Grant
- 2008-03-27 EP EP08742326.5A patent/EP2276483B1/en not_active Revoked
- 2008-03-27 PT PT87423265T patent/PT2276483E/pt unknown
- 2008-03-27 BR BRPI0822398A patent/BRPI0822398B8/pt active IP Right Grant
- 2008-03-27 AU AU2008353468A patent/AU2008353468B2/en active Active
- 2008-03-27 KR KR1020147029963A patent/KR20140142323A/ko not_active Application Discontinuation
- 2008-03-27 RU RU2010143907/04A patent/RU2471782C2/ru active
- 2008-03-27 CA CA2718601A patent/CA2718601A1/en not_active Abandoned
-
2010
- 2010-09-16 ZA ZA2010/06663A patent/ZA201006663B/en unknown
- 2010-09-16 IL IL208216A patent/IL208216A0/en unknown
-
2013
- 2013-09-10 IL IL227991A patent/IL227991A0/en unknown
-
2014
- 2014-06-26 HR HRP20140609AT patent/HRP20140609T1/hr unknown
- 2014-07-23 CY CY20141100557T patent/CY1115361T1/el unknown
-
2015
- 2015-07-14 NO NO2015017C patent/NO2015017I1/no not_active Application Discontinuation
-
2016
- 2016-08-22 IL IL247411A patent/IL247411A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2010010454A (es) | 2010-12-20 |
EP2276483A1 (en) | 2011-01-26 |
IL227991A0 (en) | 2013-09-30 |
NZ588104A (en) | 2012-11-30 |
JP2011515463A (ja) | 2011-05-19 |
RU2010143907A (ru) | 2012-05-10 |
HRP20140609T1 (hr) | 2014-08-15 |
BRPI0822398B1 (pt) | 2018-01-16 |
DK2276483T3 (da) | 2014-06-10 |
NO2015017I1 (no) | 2015-07-27 |
EP2695616A1 (en) | 2014-02-12 |
KR20150038547A (ko) | 2015-04-08 |
PT2276483E (pt) | 2014-07-25 |
CY1115361T1 (el) | 2017-01-04 |
PL2276483T3 (pl) | 2014-09-30 |
SI2276483T1 (sl) | 2014-08-29 |
JP5474043B2 (ja) | 2014-04-16 |
MX359839B (es) | 2018-10-12 |
IL247411A0 (en) | 2016-11-30 |
AU2008353468A1 (en) | 2009-10-01 |
AU2008353468B2 (en) | 2015-08-06 |
ZA201006663B (en) | 2012-02-29 |
CA2718601A1 (en) | 2009-10-01 |
IL208216A0 (en) | 2010-12-30 |
ES2476252T3 (es) | 2014-07-14 |
EP2276483B1 (en) | 2014-05-07 |
KR20100132045A (ko) | 2010-12-16 |
KR20140142323A (ko) | 2014-12-11 |
BRPI0822398A2 (pt) | 2014-11-18 |
RU2471782C2 (ru) | 2013-01-10 |
CN102046167A (zh) | 2011-05-04 |
WO2009120167A1 (en) | 2009-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0822398B8 (pt) | forma sólida cristalina e composição farmacêutica que a compreende | |
LTPA2018014I1 (lt) | Farmacinė kompozicija 514 | |
LTPA2018005I1 (lt) | Farmacinė kompozicija | |
NL300891I2 (nl) | Lotilaner en zouten daarvan | |
BRPI0721651A2 (pt) | Composição farmacêutica | |
BRPI0919466A2 (pt) | composição farmacêutica para liberação modificada | |
BRPI0920521A2 (pt) | combinação farmacêutica | |
BRPI0917900A2 (pt) | fixadores temporários | |
BRPI0924135A2 (pt) | composição farmacêutica sólida compreendendo anlodipino e losartan | |
RU2493831C3 (ru) | Фармацевтические композиции | |
BRPI0813775A2 (pt) | Composição | |
ATE528048T1 (de) | Schweisshemmende/desodorierende zusammensetzung | |
DK2120884T3 (da) | Farmaceutisk sammensætning | |
DK2285413T3 (da) | Farmaceutisk sammensætning | |
BRPI0810557A2 (pt) | composição | |
BRPI0811274A2 (pt) | Composição | |
DK2209464T3 (da) | Farmaceutisk sammensætning mod malaria | |
BRPI0921313A2 (pt) | composição farmaucêutica | |
DK2262486T3 (da) | Quetiapin sammensætning | |
DK2271618T3 (da) | Farmaceutiske forbindelser | |
BRPI0820198A2 (pt) | composições farmacêuticas | |
BRPI0807882A2 (pt) | Forma de dosagem | |
BRPI0811002A2 (pt) | Composição biofertilizante | |
BRPI0912171A2 (pt) | composição farmacêutica | |
BRPI0822782A2 (pt) | composição farmacêutica que compreende rosuvastatina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B65X | Notification of requirement for priority examination of patent application | ||
B65Y | Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117) | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
B16B | Notification of grant cancelled [chapter 16.2 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 16.1 NA RPI NO 2454 DE 16/01/2018 POR TER SIDO INDEVIDA. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/03/2008, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A PUBLICACAO NA RPI 2452 DE 02/01/2018 QUANTO AO TITULO. |
|
B25A | Requested transfer of rights approved |